Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
- 6 May 2009
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (6) , 589-595
Abstract
Aim: To compare the tolerability and efficacy of vildagliptin to pioglitazone as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy over 1‐year duration. Methods: This 52‐week, multicentre, randomized, active‐controlled study compared vildagliptin (50 mg b.i.d., n = 295) and pioglitazone (30 mg daily, n = 281) in patients with inadequate glycaemic control [haemoglobin A1c (HbA 1c ) 7.5–11%] receiving a stable dose of metformin (≥1500 mg). The primary objective was to demonstrate non‐inferiority of vildagliptin at 24 weeks in the change in HbA 1c from baseline. The objective of the additional 28 weeks of the study was to assess long‐term safety, while also assessing mean change from baseline to study end in HbA 1c , fasting plasma glucose and body weight. Results: When added to a stable dose of metformin (mean baseline dose approximately 2 g/day), the non‐inferiority of HbA 1c lowering of vildagliptin to pioglitazone over 24 weeks was established at the non‐inferiority margin of 0.3% (between‐group difference = 0.1%). During the remaining 28 weeks, comparable HbA 1c decreases were recorded in both groups. Overall adverse event (AE) rates were similar in both groups, as was the occurrence of peripheral oedema. Hypoglycaemia occurred rarely in both groups. Serious AEs occurred more frequently with pioglitazone group. While mean body weight increased significantly in the pioglitazone group (+2.6 kg) from baseline, there was no significant weight gain with vildagliptin (+0.2 kg). Conclusions: When added to metformin, vildagliptin demonstrates favourable safety and tolerability over 1 year. Vildagliptin provided additional HbA 1c lowering to that achieved with metformin alone and comparable to that achieved with pioglitazone, with only pioglitazone causing weight gain.Keywords
This publication has 17 references indexed in Scilit:
- Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study*Diabetes, Obesity and Metabolism, 2007
- Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With MetforminDiabetes Care, 2007
- Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose StudyHormone and Metabolic Research, 2007
- Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 DiabetesDiabetes Care, 2007
- Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2007
- Diabetes, TZDs, and Bone: A Review of the Clinical EvidencePPAR Research, 2006
- Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 DiabetesHormone and Metabolic Research, 2006
- Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trialCurrent Medical Research and Opinion, 2006
- Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose responseDiabetes, Obesity and Metabolism, 2005
- Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyDiabetes/Metabolism Research and Reviews, 2005